SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...

EST Aptevo Therapeutics (APVO) trading resumesPick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid ...

Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing ...

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in ...

Stock analysts at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the ...

In recent trading, Aptevo Therapeutics Inc (APVO) stock price has shown some volatility, fluctuating -43.59% over the last five trades and -44.63% over the past 30 trades. This represents a notable ...

RCI Hospitality Holdings, Inc. plans to file its 10-K and report financial results for the fiscal 2024 fourth quarter and year ended September 30, 2024 after the market closes on Monday, December 16.